Pharmaceuticals
ExoCoBio Receives Japanese Patent for Alleviating Dermatitis with Adipose Stem Cell-Derived Exosome
* To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment * To prove the technological feasibility of ExoSCRT™ for the mass-production of the world's best exosomes with high efficacy SEOUL, Korea, May 9, 2022 /PRNewswire/ -- ExoC...
2022-05-09 07:00
5300
Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report
DURHAM, N.C. and BEIJING, May 7, 2022 /PRNewswire/ -- Brii Biosciences Limited
2022-05-07 09:00
6762
Antengene to Participate in Three Upcoming Investor Conferences in May/June
CICC Healthcare Industry Forum 2022: May 9th to 12th BTIG Virtual China Biotech Day: June 1st Citi's 3rd Pan-Asia Regional Investor Conference 2022: June 8th to June 10th SHANGHAI and HONG KONG, May 6, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading inno...
2022-05-06 08:30
3734
Insilico Medicine expands synthetic lethality portfolio with the nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers
NEW YORK, May 6, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-de...
2022-05-06 05:00
3857
Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers
NEW YORK, May 5, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-de...
2022-05-05 23:00
3767
HOYA Vision Care Releases Results of First of its Kind Six-Year MiYOSMART Spectacle Lens Follow-up Clinical Study
Strong evidence shows continued long-term lens effectiveness in slowing myopia progression in children BANGKOK, May 5, 2022 /PRNewswire/ -- HOYA Vision Care, a leader in optical technology innovation, shared the results of asix-year follow-up clinical study on its award winning MiYOSMART spectac...
2022-05-05 22:12
6141
TIKOMED and IQVIA announce a strategic collaboration for the development of TIKOMED's lead drug platform candidate ILB®
VIKEN, Sweden, May 5, 2022 /PRNewswire/ -- Today, Swedish biopharmaceutical company TikoMed AB and IQVIA announce a key strategic collaboration with the aim to accelerate the development of TikoMed's lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative p...
2022-05-05 20:40
1938
Clinical Trial Approval For ReCOV In The PRC And The Overseas Clinical Trial Progress Of ReCOV
TAIZHOU, China, May 5, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group",Stock code:2179.HK) is pleased to announce that the Company has recently received the clinical trial approval (the "Clinical Trial Approval") for its recombin...
2022-05-05 11:55
4319
First Patient Dosed in Phase II Renal Cancer Theranostics Study
MELBOURNE, Australia and INDIANAPOLIS, May 5, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in the 'STARLITE 2' Phase II study of the Company's investigational renal cancer therapy, TLX250 (177 Lu-DOTA-girentu...
2022-05-05 05:00
3380
Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*
LUGANO, Switzerland, and SINGAPORE, May 4, 2022 /PRNewswire/ -- Juniper Biologics Pte Ltd, a science-led healthcare company focused on researching, developing and commercializing novel therapies, and Helsinn Group, a fully integrated, global biopharma company with a diversified pipeline of innova...
2022-05-04 14:00
2865
China Mobile Hong Kong Launches Online Medical App "Dr. HK"
Four Major Features Providing Doctor Consultation and Prescription While Staying at Home Medicine Doorstep Delivery in 4 hours at the earliest Free of Charge Video Consultation, Medication and Delivery for First 500 Users HONG KONG, May 4, 2022 /PRNewswire/ -- With the rise of the digital lifest...
2022-05-04 12:00
6308
Servatus strengthens Board with appointment of biopharmaceutical division head at Boehringer Ingelheim, Dr Uwe Buecheler
* New Board appointment deepens and consolidates Servatus' extensive commercial and scientific expertise for its global biotherapeutics programs * Dr Buecheler joins as Non-Executive Director from leading pharmaceutical giant Boehringer Ingelheim inGermany, where he is both Senior Vice Preside...
2022-05-02 07:36
4652
Asia Pacific Initiative on Reproduction (ASPIRE) 2022 Congress: Linking male infertility diagnosis with the window to future health trajectories
SINGAPORE, May 1, 2022 /PRNewswire/ -- Male infertility factors are emerging as likely biomarkers for later life health events including hospital treatments and possible premature death from conditions such as cancer, cardiovascular and metabolic diseases. Lifestyle and social factors, includi...
2022-05-01 13:30
5544
Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals
LONDON, April 30, 2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceuticals and Hikma have entered into a commercialisation an...
2022-04-30 02:08
3143
Transcenta to Present Clinical Trial Data of TST001 and MSB0254 at 2022 ASCO Annual Meeting
SUZHOU, China, April 29, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the abstracts o...
2022-04-29 10:33
4342
Transcenta Announces First Patient Dosed in China Study of Anti-sclerostin Monoclonal Antibody TST002 for the Treatment of Osteoporosis
SUZHOU, China, April 28, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the successful dosin...
2022-04-28 17:06
3238
CStone to present the latest clinical results of anti-PD-L1 antibody sugemalimab and anti-PD-1 antibody nofazinlimab at ASCO 2022
* Results from GEMSTONE-201 study of sugemalimab, the first successful registrational clinical study to date evaluating an anti-PD-(L)1 antibody targeting patients with relapsed or refractory extranodal natural killer/T-cell lymphoma, will be presented in an oral abstract session * The protoc...
2022-04-28 08:00
3997
FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial
AUSTIN, Texas, April 27, 2022 /PRNewswire/ -- Direct Biologics, a regenerative biotechnology company with a groundbreaking extracellular vesicle (EV) platform technology, announced today that the FDA has approved the company to proceed with its Phase 3 clinical trial using its investigational EV ...
2022-04-27 00:09
3990
Seegene unveils world's first commercialized '3 Ct' PCR assay
* Provides Ct value of three targets in one channel; '3 Ct' PCR assay to launch in H1 * "Dream MDx technology" developed based on Seegene's 20-year expertise; combines 19 different patented technologies, including DPO™, TOCE™, MuDT™ * '3 Ct' to lay foundation for automated syndromic testing ...
2022-04-26 20:32
2654
Holmusk Announces Publication of Seminal Paper on Real-World Evidence (RWE) Platform NeuroBlu
NEW YORK, April 26, 2022 /PRNewswire/ -- Holmusk, a leading global data science and health technology company building the world's largest real-world evidence (RWE) platform for behavioral health, is pleased to share with the scientific community in-depth details about its platform via thepublica...
2022-04-26 19:30
2708
Week's Top Stories
Most Reposted
Futurise Impact Report 2025 Highlights Progress in Regulatory Innovation Future-Ready Technologies
[Picked up by 272 media titles]
2026-09-09 13:26
Hyundai Motor Company Becomes Official Automotive Partner of the UEFA Champions League
[Picked up by 266 media titles]
2026-09-07 13:00
Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
[Picked up by 264 media titles]
2026-09-10 15:00People See One Brand. The Internet May Show Them Hundreds More.
[Picked up by 264 media titles]
2026-09-07 09:00Nuix Expands Generative AI for Legal Review, Debuts AI Chat for Case Data
[Picked up by 262 media titles]
2026-09-07 09:40Most Read
AIA Australia, Long Service Corporation, New Zealand Police and RMBL Investments Named 2026 Appian APJ Innovation Award Winners
2026-09-07 11:28
8846
Sungrow Calls for Scenario-based and integrated systems to Accelerate the Next Phase of the Renewable Energy Transition
2026-09-09 22:26
7427
Hyundai Motor Company Becomes Official Automotive Partner of the UEFA Champions League
2026-09-07 13:00
6845